Science 37 and Xperiome in Rare Disease Studies

Study teams often face challenges in maintaining detailed and accurate documentation of risk signals.

Jared Baeten, Vice President, Clinical Development, HIV Franchise Head at Gilead Sciences highlights how awareness and clinical innovation have transformed research in the HIV space.

Johnson & Johnson’s TAR-200 is currently in clinical trials for patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer who are ineligible for or elected not to receive bladder removal surgery.

Insightful sound bytes from KOLs attending SCOPE EUROPE 2023.

Regardless of alliances, providers must be aligned on the latest scientific approaches in the clinical technology space.

Research shows GenAI has greater potential for a more immediate impact than previous digital technologies implemented in healthcare.